chrisvoncsefalvay/vaers-outcomes huggingface dataset:
PT admitted with Covid on 4/18/21.  SARS-COVID-19 resulted 04/19/21 02:26. Patient has documented history of transplant 2018 and on immunosuppression. PT received dose 1 of Moderna vaccine Lot 014M20A on 2/26/21. PT received dose 2 of Moderna vaccine Lot 037A21B on 3/26/21.
The day after second COVID vaccine, patient developed flu-like symptoms of fever, cold chills, nausea, and no appetite. Symptoms lasted 1.5 days.
Received dose #1 on 2/11/21 and dose #2 on 3/11/21.     I have had mild tinnitus for about 14 years, about a 2 on a scale of one to ten.   About one week after the second dose I noticed that the ringing in my ears is much louder, probably a four or five. I can think of no other reason other than the vaccine for this to occur.   The increased volume has not subsided over the past four days.  I have not required medical attention for this event.
bad reaction to the second shot; friend is female and she had to lied in bed all day; Fatigue; headache; pain in arm; migraine; muscle pain; Malaise; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION COMPLICATION (bad reaction to the second shot), BEDRIDDEN (friend is female and she had to lied in bed all day), FATIGUE (Fatigue), HEADACHE (headache) and PAIN IN EXTREMITY (pain in arm) in a 19-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     The patient's past medical history included No adverse event. Concomitant products included PROLIFE for Asthma, ASCORBIC ACID, VITAMIN D3, ZINC and VITAMIN B COMPLEX for an unknown indication.    On an unknown date, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 2 dosage form. On an unknown date, the patient experienced VACCINATION COMPLICATION (bad reaction to the second shot), BEDRIDDEN (friend is female and she had to lied in bed all day), FATIGUE (Fatigue), HEADACHE (headache), PAIN IN EXTREMITY (pain in arm), MIGRAINE (migraine), MYALGIA (muscle pain) and MALAISE (Malaise). At the time of the report, VACCINATION COMPLICATION (bad reaction to the second shot), BEDRIDDEN (friend is female and she had to lied in bed all day), FATIGUE (Fatigue), HEADACHE (headache), PAIN IN EXTREMITY (pain in arm), MIGRAINE (migraine), MYALGIA (muscle pain) and MALAISE (Malaise) outcome was unknown.
This is a spontaneous report from a Medical Assistant who called on behalf of the Physician regarding a patient. A 64-year-old female patient was given the first dose of PREVNAR 13 (Lot J80525, exp 01Jan2016), intramuscularly in the upper deltoid, on 12Aug2014 at 0.5 mL, by a nurse in the doctor's office. Medical history included hypertension (2007), high cholesterol (2007), and glaucoma (2007). There were no concomitant vaccines or concomitant medication. The patient experienced red hot arm at the site of the injection, arthralgia and body temperature rose to 101 on "30Jan2015". The patient experienced the problems within 24 hours of injection and then for several days; and "he" reported a month later. This patient was experiencing this problem for the first time. The patient didn't require any visits to the hospital or emergency. The patient recovered from the events on an unspecified date. In the reporter's medical opinion, the events were related to PREVNAR 13. Follow-up (12Mar2015): Follow-up attempts completed. No further information expected.
received/ subcutaneously instead of intramuscularly; This case was reported by a consumer via call center representative and described the occurrence of intramuscular formulation administered by other route in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix (received 1st dose on an unknown date).   On an unknown date, the patient received the 2nd dose of Shingrix (subcutaneous). On an unknown date, unknown after receiving Shingrix, the patient experienced intramuscular formulation administered by other route. On an unknown date, the outcome of the intramuscular formulation administered by other route was unknown.  Additional details were provided as follows: This case was reported by patient itself. The age at vaccination was not reported. The patient received Shingrix subcutaneously instead of intramuscularly which led to intramuscular formulation administered by other route. The reporter declined to provide any other additional information or answer adverse event questions when asked.   She stated that, she wanted to speak to her healthcare professional first and would call back later with further details.   Provided caller with phone number to for healthcare professional to call for advice. The reporter declined to provide healthcare professional information. The reporter did not consent to follow up with her healthcare professional.
Received first Moderna vaccination dose on 14MAY2021.  On 23MAY2021, a red and slightly itchy rash appeared at the site of injection .  Symptoms are very mild.   No treatment sought or received (as of 24MAY2021).
Injection was very painful, I told the pharmacist the inj location was too high, close to shoulder. Since inj, I've experienced pain shooting down toward elbow and up toward shoulder and back.
cough; shortness breath; high temperature; diarrhea; nausea; vomiting; This spontaneous case was reported by a patient and describes the occurrence of COUGH (cough), DYSPNOEA (shortness breath), PYREXIA (high temperature), DIARRHOEA (diarrhea) and NAUSEA (nausea) in a 67-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 012120A) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.     No Medical History information was reported.    On 19-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 30-Jan-2021, the patient experienced COUGH (cough), DYSPNOEA (shortness breath), PYREXIA (high temperature), DIARRHOEA (diarrhea), NAUSEA (nausea) and VOMITING (vomiting). At the time of the report, COUGH (cough), DYSPNOEA (shortness breath), PYREXIA (high temperature), DIARRHOEA (diarrhea), NAUSEA (nausea) and VOMITING (vomiting) was resolving.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Concomitant medications reported were blood pressure, anti-depressive, cholesterol and allergies pills.  No treatment medications were provided by the reporter.; Sender's Comments: Based on the current available information and temporal association between the use of the product and the start date of the events, a causal relationship cannot be excluded.
the patients husband called the pharmacy on 9/24/2020 stating that she received the flu vaccine on 9/23/2020 and that overnight she experienced diarrhea with bloody stools. I informed him that though diarrhea was listed as a possible side effect, I couldn't find any information on bloody stools. I asked if she was taking any blood thinners, but her husband said she wasn't.  I advised  him to seek emergency services on her behalf asap, however he stated that they would prefer to monitor the symptoms and see how she was doing, before seeking emergency services.  I called the patient on 9/25/20 to check on her and she said she was doing better, the symptoms had subsided. I had reviewed her medication profile and notified her at this point that the elmiron or the clopidogrel may have been responsible for the bloody stools, and once more advised her to seek medical attention. this time via her primary care physician ( since she said her symptoms had subsided)
Reporting that patient has had no ill effects or adverse effects from getting 2 different vaccines.  Patient would like to get 2nd moderna vaccine to increase his coverage but I called and let him know that this was against guidelines and he is considered fully vaccinated.  Pharmacy clinical team communicated to the pharmacy that those should be reported to VAERS.
Fever; muscles aches; back pain; nausea; This is a spontaneous report from a contactable consumer (patient). A 29-year-old female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE ; lot number and expiration date were not reported), via an unspecified route of administration, in Left Arm on 11Apr2021 at 11:00 (at the age of 29-years-old) at single dose for COVID-19 immunization. The patient's medical history was not reported. Concomitant medication included Birth control received within 2 weeks of vaccination. patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. Patient had no allergies to medications, food or other products. Patient was not pregnant at the time of vaccination. Prior to vaccination, the patient was not diagnosed with COVID-19 and since the vaccination has not been tested for COVID-19. The patient had most recent COVID-19 vaccine at  Health Clinic/Administration facility. The patient experienced fever, muscles aches, back pain and nausea on 11Apr2021 at 16:00 after vaccination. No treatment was given for the events. The outcome of the events was recovering.  No follow-up attempts are possible; information about lot/batch number cannot be obtained.
runny nose; This spontaneous case was reported by a consumer and describes the occurrence of RHINORRHOEA (runny nose) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     The patient's past medical history included No adverse event.    On 08-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 11-Jan-2021, the patient experienced RHINORRHOEA (runny nose). At the time of the report, RHINORRHOEA (runny nose) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Reporter did not allow further contact
Soreness at injection site; headache; drowsiness; This is a spontaneous report received from a contactable reporter (Consumer or other non HCP). The reporter is the patient.  A patient (no qualifiers provided) received BNT162B2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection) (Lot number: EL3247) as dose number unknown, single for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: VACCINATION SITE PAIN (non-serious), outcome "unknown", described as "Soreness at injection site"; HEADACHE (non-serious), outcome "unknown", described as "headache"; SOMNOLENCE (non-serious), outcome "unknown", described as "drowsiness".  No follow-up attempts are possible. No further information is expected.
Initial case report received from a healthcare professional on 14 Oct 2014. A 53-year-old female patient, whose medical history and concomitant medications were not reported, had received a dose of FLUZONE HD (Lot number U5022BA, intramuscularly in the left deltoid) on 08 October 2014. On 14 October 2014, the patient complained of fever 102.2 Fahrenheit and congestion and back pain. The patient had required ER visit. Corrective treatment details and laboratory details were not reported. The patient had recovered on an unspecified date. Document held by sender: None. Follow up information received from health care professional on 05 January 2015. The patient did not receive any other vaccinations within 4 weeks of vaccinations of FLUZONE HD and no previous dose of FLUZONE HD. The patient had medical history of anxiety disorder, arthritis and "chrons dz" (Crohn's disease). Patient had received AUGMENTIN from 14 Oct 2014 to 24 Oct 2014 for 10 days twice a day as a corrective treatment and medication given by staff of nursing home included: NEXIUM 40 Mg tablet daily, potassium chloride 20 miliequivalent table daily, LASIX 40 mg tablet twice a day, ABILIFY 10 mg tablet daily, Trazodone tablet 150 mg daily, LYRICA 150 tablet twice daily, VALIUM 5 mg tablet three times a daily, ULTRAM 50 mg tablet every 4 hours as needed and FLAGYL 500 mg tablet twice daily for 7 day from 12 December 2014 to 19 December 2014. Laboratory investigations were unavailable. On 24 October 2014 patient was recovered from the event.
Pain and burning both arms for last 8 hours.  Fatigue and muscle pain.  Pain at injection.  Tachycardia
Joint pain, chronic fatigue, depression, headaches, muscular aching, fibromyalgia symptoms
11:45 am: Patient received his first pediatric dose of the Pfizer vaccine. 12:15 pm: Patient complaint of shortness of breath and "tickly in the throat," then moved to a gurney for closer observation. 12:16 pm: Pulse ox 100%, Pulse 97, BP of the left arm 134/87. Appeared flushed in the face, and appeared to be without increased work of breathing. 12:19 pm: Doctor arrived at patient's side and evaluated him. 12:20 pm: Pulse ox 100%, Pulse 94. 12:25 pm: Another doctor arrived at patient's side and evaluated him.Temp Oral 96.0 F. 12:30 pm: Doctor ordered patient to receive 10mL oral of Zyrtec, and continued to monitor for 15 minutes more. 12:33 pm: Pulse 97% and HR 94. 12:36 pm: Patient complained of slightly "tickly throat," pulse ox 96%; then pulse ox discontinued. 12:38 pm: BP of the left arm 123/72 pulse 83. Patient appeared stable enough to go home with family. Recommended mother of patient to go to ED if his conditions worsen, and to make a follow-up appointment with primary physician.
No actual adverse event occured;required to be reported as a vaccine administration error per CDPHE. Monovalent mRNA Covid-19 vaccine booster administered to patient >12 year old after FDA's authorization of bivalent booster (08/31/22).
Feeling warm (no fever), body ache, fatigue, left arm injection site - swelling, pain, warm.
Information has been received from a certified midwife nurse regarding a patient of unknown age and gender. In 2010, the patient was vaccinated with the first dose of GARDASIL (dose, route and lot number were not provided). In March 2014, the patient was vaccinated with the second dose of GARDASIL (dose, route and lot number were not provided). In July 2014, the patient was vaccinated with the third dose of GARDASIL (dose, route and lot number were not provided). No adverse effects reported. Additional information has been requested.
pt recv vax 17OCT97 &18OCT97 pt devel abd pain & sl fever;19OCT97 recv vax #2 devel abd pain all day;temp to103 (oral);20OCT97 abd pain subsided;temp @ 100;21OCT97recovered;no rash/urticaria;
Received vaccine past published expiry; This spontaneous case was reported by a health care professional and describes the occurrence of EXPIRED PRODUCT ADMINISTERED (Received vaccine past published expiry) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 050e21a) for COVID-19 vaccination.     No Medical History information was reported.    On 20-Oct-2021, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 20-Oct-2021, the patient experienced EXPIRED PRODUCT ADMINISTERED (Received vaccine past published expiry). On 20-Oct-2021, EXPIRED PRODUCT ADMINISTERED (Received vaccine past published expiry) had resolved.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown Route), the reporter did not provide any causality assessments.   No concomitant medications were mentioned. No treatment details were reported. No adverse reactions reported. Dates moved from freezer to refrigerator were on dates of administration   This case was linked to MOD-2021-403046 (Patient Link).
53 y/o M w/ known cirrhosis, ETOH abuse, chronic leukopenia and thrombocytopenia, hx of HE, psoriasis on Tremfya injections, HTN, HL, reflux esophagitis - presents to the ER d/t generalized malaise, subjective feeling of fevers, fatigue and weakness. States that symptoms just started this AM and woke up with these symptoms. He also felt nauseated and vomited 3x while in the ER. He denies any actual SOB and has no cough, but reports that today felt like his breathing is labored primarily because of fatigue. He also is complaining of soreness in the RUQ though this is somewhat chronic and intermittently occurs.    In the ER, pt was found to be febrile, and met sepsis criteria by way of his chronic thrombocytopenia. He also had an elevated lactic acid of 3.4. COVID test was positive. He is not hypoxic. CXR negative. UA pending (pt denies any symptoms related to UTI). Na level at 129 and NH4 is 84 (though pt is not confused).    Pt covid positive.  Symptom onset 1/30/23 Pt completed remdesivir.  No decadron as no hypoxemia.   Stable thrombocytopenia and leukopenia.  Appreciate heme/onc consult.  Psych consulted for meds for PTSD and felt meds precluded due to plt interaction and bleeding risk.  Pt with intermittent headache, will give small amount of roxicodone (avoiding tylenol due to cirrhosis and nsaids due to bleeding risk).   Pt knows his life depends on complete etoh cessation. Pt stable for dicharge to home or to inpatient rehab facility
Fatigue; stomach issues; This case was reported by a consumer via call center representative and described the occurrence of fatigue in a 71-year-old male patient who received Flu unspecified (Influenza vaccine) for prophylaxis.   Co-suspect products included COVID-19 VACCINE (COVID VACCINE) for prophylaxis.   Concomitant products included Nucala.   On 5th October 2022, the patient received Influenza vaccine and COVID VACCINE. On 6th October 2022, 1 days after receiving Influenza vaccine, the patient experienced fatigue and gastric disorder. On an unknown date, the outcome of the fatigue and gastric disorder were not recovered/not resolved.  It was unknown if the reporter considered the fatigue and gastric disorder to be related to Influenza vaccine.     Linked case(s) involving the same patient:  US2021211498   Additional Information: GSK receipt date: 06-OCT-2022 Reporter's comment: The reporter was the patient who had self-injected his last dose of Nucala Al one month ago.  The reporter stated that he had received a covid vaccine and a flu vaccine on 05th October 2022 and had experienced fatigue and stomach issues on 06th October 2022.  The reporter was inquiring if he could take his planned dose of Nucala Al on 06th October 2022. Provided medical advice disclaimer and Healthcare Professional (HCP) referral.  The lot no and expiration date was unknown. Provided product education. The reporter had consented to follow-up with the Healthcare Professional (HCP). Additional supportive information: It was unknown if the reporter considered the fatigue and gastric disorder to be related to Covid Vaccine. This case was linked with US2021211498 which was reported for same patient.; Sender's Comments:  US-GLAXOSMITHKLINE-US2021211498:same patient
This case was reported by a other health professional via call center representative and described the occurrence of extra dose administered in a 29-year-old male patient who received FLUARIX QUADRIVALENT (batch number N933S, expiry date 30th June 2018). Concomitant products included FLUARIX QUADRIVALENT. On 11th December 2017, the patient received the 2nd dose of FLUARIX QUADRIVALENT. On 11th December 2017, unknown after receiving FLUARIX QUADRIVALENT, the patient experienced extra dose administered. On an unknown date, the outcome of the extra dose administered was unknown. Additional details were received as follows: On 18th September 2017, the patient received a dose of FLUARIX. The patient received another dose on the day of reporting, which led to extra dose administered.
Directly after the vaccination, I was very sore and fatigued. After about 3 weeks, I went to location and when I reached over my head I received a sharp stinging pain in my shoulder, diagnosed with inflamed should joint where I received 2 cortisone shots for the pain. I then could hardly make a fist and my hands and  wrist swelled up in the early part of March. March 10th, I went to urgent care and from receiving a blood tests I was referred to a rheumatologist. All of this occurred within 5 weeks of the shot. I then met with the Rheumatologist on 24th of March and speak with them often for care and treatment. Symptoms are being treated with a multiple combination of immuno-suppressant medications, low dose prednisone , Mycophenolic, Hydroxychloroquine, since March.  Symptoms have improved dramatically since using these prescriptions.
Itching; This is a spontaneous report from a contactable consumer and nurse. A female patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Solution for injection, Batch/Lot number was not reported) via an unspecified route of administration on an unspecified date as DOSE 1, SINGLE for covid-19 immunisation. The patient received co-suspect lenvatinib mesilate (LENVIMA), oral from an unspecified date (Batch/Lot Number: 1265572; Expiration Date: 29Feb2024) to an unspecified date, at 10 mg, 1x/day for uterine cancer. No known allergies and medical history were reported. Concomitant medication included nitrofurantoin; potassium; sodium bicarbonate; gabapentin; magnesium; pembrolizumab (KEYTRUDA); amlodipine besilate taken for an unspecified indication, start and stop date were not reported. The patient previously took penicillin g potassium, cipro [ciprofloxacin], iodine. The patient experienced itching on an unspecified date. It was reported that Patient got her COVID VACCINE 3 weeks ago and will get her 2ND one 5/22/21 and have been itching since getting the vaccine. The patient underwent lab tests and procedures which included blood pressure measurement: elevated on an unspecified date, blood pressure measurement: 121/71 on 28Apr2021, blood pressure measurement: 154/101 on an unknown date in 2021. The action taken in response to the events for bnt162b2 was not applicable, for lenvatinib mesilate was unknown. Therapeutic measures benadryl was taken as a result of itching which has made helped but made her sleepy and discussed alterative antihistamines. The clinical outcome of the event was unknown.  Information about lot/batch number cannot be obtained. No further information expected.
Patient dropped in this a.m. stating that he awoke the morning of 18 October 2003 with malaise, general achiness, and crankiness ( per a close friend). This has continued until this a.m. No fever. Has slight pain at injection site, but no swelling or heat over area.
This spontaneous report was received from a nurse practitioner and refers to an unspecified patient of unknown age and gender. The patient's medical history, concurrent conditions and concomitant medications were not reported. On 28-JAN-2017, the patient was vaccinated with the improperly stored dose of PROQUAD subcutaneously (dose was not reported) (lot # M031568, expiration date 24-DEC-2017) for prophylaxis. There were no adverse effects reported. Administered dose of vaccine experienced the temperature excursion greater than 5 degrees Fahrenheit and less than 14 degrees Fahrenheit (6.1 degrees Fahrenheit) for 41 hours and 20 minutes. Data logger was involved. This is one of several reports received from the same reporter. Additional information has been requested.; Sender's Comments: US-009507513-1702USA004122: US-009507513-1702USA004127: US-009507513-1702USA004124: US-009507513-1702USA004125: US-009507513-1702USA004126: US-009507513-1702USA004121: US-009507513-1702USA004123: US-009507513-1702USA004176:
- Sore arm that lasted 4 days since injection - Mild body ache and warmth of body that started 12 hours after injection and lasted 2 hours.
Mom describes swelling of rt arm and neck pm of injection.  Contacted private MD on 9/29/06 pm. Seen in office on 10/02/06 and given "steroid shot".
Observation 6/25/22-6/27/22 dizziness, hypotensive, dyspnea, arrhythmia, AKI,
Severe headache the first evening of the shot on 3/09 around 11pm.  Had symptoms of the shot for 2-3 weeks. Develop headaches each day after ranging from mild to severe. Develop a fever starting the 3/31. Left work early to get tested for Covid-19. Received my results back on 4/2 testing negative.  Having headaches and congestion everyday until 4/8.